SCHEMBL6492987

SCHEMBL6492987

COC(=O)c1cc([N+](=O)[O-])c(NC(C)=O)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
ALDH1A1 P00352 2/20 0.53
GALR2 O43603 1/20 0.53
MITF O75030 1/20 0.53
POLB P06746 1/20 0.53
HSP90AA1 P07900 1/20 0.53
HPGD P15428 1/20 0.53
XBP1 P17861 1/20 0.53
CCR6 P51684 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KMT2A Q03164 4/20 0.51
MEN1 O00255 2/20 0.51
KDM4E B2RXH2 1/20 0.49
SLC9A1 P19634 1/20 0.49
MAPT P10636 2/20 0.47
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7474176 0.89 LMNA (0.60) LMNANPSR1ALDH1A1GALR2MITF
SCHEMBL8954112 0.88 SMN1; SMN2 (0.58) LMNANPSR1ALDH1A1GALR2MITF
SCHEMBL21989034 0.87 SLC9A1 (0.52) LMNANPSR1ALDH1A1GALR2MITF
SCHEMBL3915677 0.86 SLC9A1 (0.51) LMNANPSR1ALDH1A1GALR2MITF
SCHEMBL9899099 0.86 MEN1 (0.47) LMNAPOLBKMT2AMEN1KDM4E
SCHEMBL30035016 0.86 MEN1 (0.47) LMNAPOLBKMT2AMEN1KDM4E
SCHEMBL2128713 0.84 SMN1; SMN2 (0.54) LMNANPSR1ALDH1A1GALR2MITF
SCHEMBL8767018 0.84 LMNA (0.58) LMNANPSR1ALDH1A1GALR2MITF
SCHEMBL3915656 0.84 SLC9A1 (0.56) LMNANPSR1ALDH1A1GALR2MITF
SCHEMBL8513944 0.84 MAPT (0.55) LMNANPSR1ALDH1A1GALR2MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed
EP-0196910-B1 Benzo[a]phenazine derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1991-01-02 EP disclosed
US-4686292-A Benzo[α]phenazine antitumor agents TAISHO PHARMACEUTICAL CO., LTD. (JP) 1987-08-11 US disclosed
EP-0196910-A2 Benzo[a]phenazine derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1986-10-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A LMNA 2742/4885NPSR1 1412/4885ALDH1A1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.